

Does your patient have NF1-associated Plexiform Neurofibromas?

If YES, he/she may be eligible for the ReNeu clinical research study.

This study will evaluate the confirmed complete and partial response rate of the study drug using volumetric MRI analysis in participants with an inoperable NF1-associated PN that is causing significant morbidity.

Key Eligibility Criteria

- ≥ 2 years of age
- Either a clinical diagnosis of NF1 using the National Institute of Health (NIH) Consensus Conference criteria, **OR** a constitutional NF1 mutation documented in a certified lab
- Target PN that is causing significant morbidity
- Target PN that is deemed inoperable
- Target PN that is amenable to MRI analysis (for those aged ≥ 18 , PN must also be amenable to percutaneous biopsy)
- Has never received therapy with PD-0325901 or any other MEK1/2 inhibitor

For more information about the ReNeu study, please contact
Hans Shuhaiber MD Director of NF clinic and PI (principal investigator)
hshuhaiber@ufl.edu

Victoria Hope CRC clinical care coordinator victoria.hope@neurology.ufl.edu
Hans Shuhaiber (352) 294-5000 (352) 273-5550 (24 hours)
Victoria Hope (352) 733-2436 Amanda Cowser (352) 733- 2435